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Searching for new anticonvulsant agents con-
stitutes an important issue for modern medicinal
chemistry. Despite broad availability of antiepileptic
drugs (AEDs) about 30% of diagnosed epileptic
seizures remain resistant to pharmacotherapy by
means of one or more drugs (1). Moreover,
antiepileptic drugs are likely to cause several
adverse effects influencing the compliance among
epilepsy patient and sometimes even threating their
lives (2). There are multiple features which new
anticonvulsant drugs should possess to overcome
currently used AEDs such as better efficacy in
resistant seizures, inhibition of epileptogenesis
process, possible usage in other central nervous sys-
tem disorders, less number of adverse effects, better
tolerability and better pharmacokinetic properties
(3, 4).
In order to identify new more favorable mole-
cules several strategies could be utilized. Screening
in different animal models of seizures is a common
way of searching for new anticonvulsants.
Although it enables rather serendipitously discov-
ery of active compounds, it is used not only for
newly synthetized molecules but also for sub-
stances with known mechanism of action and deriv-
atives of previously identified anticonvulsant
agents (5). On the other hand, there are several
ways of rational drug design of new anticonvulsants
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Abstract: A series of (E)-α-methylcinnamyl derivatives of selected aminoalkanols was synthetized and evalu-
ated for activity in central nervous system. All compounds were tested as anticonvulsants and one additionally
in antidepressant- and anxiolytic-like assays. The compounds possessed pharmacophoric elements regarded as
beneficial for anticonvulsant activity: hydrophobic unit and two hydrogen bonds donor/acceptor features. The
compounds were verified in mice after intraperitoneal (i.p.) administration in maximal electroshock (MES) and
subcutaneous pentetrazole (scPTZ) induced seizures as well as neurotoxicity assessments. Eight of the tested
substances showed protection in MES test at the dose of 100 mg/kg. The derivative of 2-aminopropan-1-ol was
also tested in 6-Hz test in mice i.p. and showed anticonvulsant activity but at the same time the neurotoxicity
was noted. The derivative of 2-amino-1-phenylethanol which possessed additional hydrophobic unit in
aminoalkanol moiety was tested in other in vivo assays to evaluate antidepressant- and anxiolytic-like activity.
The compound proved beneficial properties especially as anxiolytic agent remaining active in four-plate test in
mice at the dose of 2.5 mg/kg (i.p.). In vitro biotransformation studies of 2-amino-1-phenylethanol derivative
carried out in mouse liver microsomal assay indicated two main metabolites as a result of aliphatic and aromatic
hydroxylation or aliphatic carbonylation. To identify possible mechanism of action, we evaluated serotonin
receptors (5-HT1A, 5-HT6 and 5-HT7) binding affinities of the compounds but none of them proved to bind to
any of tested receptors.
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including identification of new molecular targets
and design their ligands according to receptor-
based pharmacophore models (6). In order to design
active compound when the exact three-dimensional
structure of the target is not known ligand-based
pharmacophore model could be used. Investigations
made in the group of antiepileptic drugs and com-
pounds in pre-clinical development possessing anti-
convulsant activity showed that some structural ele-
ments are common and may be relevant for certain
activity. Those elements arranged in appropriate
manner in three-dimensional structure were at least
one hydrophobic unit (e.g., ring), one or two elec-
tron donor atoms, and/or an NH group. Some
authors indicated the importance of so called
hydrogen bonding domain, which is formed by
electron donor atom in close distance to NH group
(7-9).
Table 1. Synthesis and chemical structures of the tested compounds [I-X].
Compound R Base/salt Configuration
I  base R,S
II base R,S
III HCl -  
IV base R,S
V base -  
VI HCl -  
VII HCl -  
VIII base R,S
VIIIa HCl R,S 
IX base trans, 
D,L
X base trans 
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Cinnamamide derivatives containing at least
two pharmacophoric domains (hydrophobic unit and
hydrogen bonding domain) proved anticonvulsant
and antidepressant activity (10-12). Previously, we
have also investigated trans-cinnamyl derivatives of
aminoalkanols (13). Cinnamyl moiety ensured the
presence of hydrophobic unit but the compounds
were devoid of hydrogen bonding domain, however
the derivatives showed moderate anticonvulsant
activity in maximal electroshock test in mice after
intraperitoneal administration. 
In the current paper, we report a series of modi-
fied (E)-cinnamyl derivatives of aminoalkanols. The
designed compounds possess at least four pharma-
cophoric domains including two hydrophobic units
and two hydrogen bonds donor/acceptor features. We
aimed to investigate how an additional methyl group
in cinnamyl domain would influence pharmacologi-
cal properties of active compounds. The compounds
were tested for their anticonvulsant activity. The
derivative which possessed additional hydrophobic
unit in aminoalkanol moiety was additionally tested
in antidepressant- and anxiolytic-like assays. We also
performed in vitro biotransformation of that com-
pound in liver microsomal assay. Additionally, in sil-
ico studies were employed to predict the major
cytochrome P450 (CYP450) isoenzymes involved in
its metabolism. Moreover, we investigated the affini-
ties to serotonin 5-HT1A, 5-HT6 and 5-HT7 receptors
to identify possible mechanism of action and other
possible activities in central nervous system.
EXPERIMENTAL
Chemistry
Apparatus and reagents
Reagents were manufactured by Alfa Aesar
(Karlsruhe, Germany). Solvents were commercially
available materials of reagent grade. Melting points
(m.p.) were determined using a B¸chi SMP-20
apparatus (B¸chi Labortechnik, Flawil, Switzer-
land) and are uncorrected. Elemental analyses were
performed on a Vario EI III elemental analyzer
(Hanau, Germany). The 1H NMR spectra were
obtained in CDCl3 or DMSO-d6 by means of a
Varian Mercury-VX 300 NMR spectrometer
(Varian Inc., Palo Alto, USA) with TMS or DMSO
as internal standard, respectively. Results of 1H
NMR are presented in the following format: chemi-
cal shift δ in ppm, multiplicity, coupling constant J
in Hertz (Hz), number of protons, protonsí position.
Multiplicities are showed as the abbreviations: s
(singlet), bs (broad singlet), d (doublet), dd (doublet
of doublets), t (triplet), m (multiplet). The IR spec-
tra were recorded on a Jasco FT/IR 410 spectrome-
ter (Gross-Umstadt, Germany) using KBr pellets
and are reported in cm-1. The purity of obtained com-
pounds was confirmed by the thin-layer chromatog-
raphy (TLC), carried out on pre-coated aluminum
sheets (silica gel 60 F-254, Merck, Darmstadt,
Germany) using mixtures of chloroform/methanol
(9 : 1 v/va)), (5 : 1, v/vb)), methanol/ethyl acetate (1 :
1, v/vc)). Spots were visualized by UV light.
Theoretical values of the partition coefficient
(LogP) of the tested compounds were calculated by
means of ACDLabs 12.0 program (ACD/LogP) and
on-line molinspiration tool (miLogP) (14).
Synthesis of the tested compounds
Trans-D,L-2-aminocyclohexanol was synthe-
sized in reaction of cyclohexene oxide with 25%
ammonia (15). The tested compounds were obtained
in two step reaction presented in Table 1. At first,
0.02 mole (2.92 g) of α-methylcinnamaldehyde
(predominantly E, 97%) were dissolved in 70 mL of
toluene in round-bottom flask. Then, 0.02 mole of
appropriate aminoalkanol was added. The reagents
were heated in Dean-Stark apparatus for 2 h.
Extensive water loss was observed and the reaction
mixture was gradually changing color to become
dark orange what indicated formation of Schiff
bases. After that time, solvent was evaporated under
reduced pressure. The obtained oily residues were
dissolved in 40 mL of methanol. Then, a solution of
sodium borohydride (0.04 mole, 1.8 g in 50 mL of
water) was being added dropwise for 30 min. The
reaction mixture was constantly mixed in water bath
containing ice-cold water. Then, methanol was
evaporated under reduced pressure. The residue was
acidified by means of 10% HCl, activated carbon
was added and the suspension was filtered. The fil-
trate was extracted with 30 mL of dichloromethane.
After separation of two phases 10% NaOH was
added to water phase. In case of compounds VIII,
IX, and X, a precipitate was observed, which was
filtered, dried and crystalized from n-hexane. For
other compounds, mixtures were extracted with two
portions of dichloromethane (50 mL + 30 mL),
extracts were combined together and dried over
anhydrous Na2SO4. Then, the solvent was evaporat-
ed under reduced pressure. The residues were crys-
tallized with n-hexane yielding the solids of com-
pounds I, II, IV and V. In case of compounds III,
VI and VII the crystallization failed and oily
residues were converted into hydrochlorides in ethyl
acetate with an excess of ethanol saturated with HCl.
Compound VIII was also converted into hydrochlo-
ride in similar conditions yielding compound VIIIa
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which was easily soluble in water. All compounds
were recrystallized, bases from n-hexane,
hydrochlorides from acetone. 
Physicochemical properties of the compounds
R,S-2-{[(2E)-2-methyl-3-phenylprop-2-en-1-
yl]amino}propan-1-ol [I]
White solid (yield 68%), m.p. 69-71OC. M.w. =
205.30. IR (KBr, cm-1): 3319, 3103, 2964, 2888,
1492, 1444, 1363, 1052, 902, 701. 1H-NMR (CDCl3,
300 MHz, δ, ppm): 1.12 (d, J = 6.4 Hz, 3H, CH-
CH3), 1.93 (d, J = 1.4 Hz, 3H, C-CH3), 2.22 (bs, 2H,
OH, NH), 2.81-2.93 (m, 1H, CH(CH3)-CH2), 3.26-
3.35 (m, 2H, CHH-OH, CHH-NH), 3.45 (dd, J =
13.6 Hz, J = 1.2 Hz, 1H, CHH-NH), 3.63 (dd, J =
10.6 Hz, J = 4.0 Hz, 1H, CHH-OH), 6.47 (s, 1H, Ar-
CH=), 7.17-7.37 (m, 5H, Ar-H Rf = 0.31a); 0.15b);
0.31c); miLogP = 2.694; ACD/LogP = 1.70 ± 0.33.
Analysis: calcd. for C13H19NO: C, 76.06; H, 9.33; N,
6.82%; found: C, 75.75; H, 9.49; N, 6.79%. 
R,S-1-{[(2E)-2-methyl-3-phenylprop-2-en-1-
yl]amino}propan-2-ol [II]
White solid (yield 71%), m.p. 52-54OC. M.w. =
205.30. IR (KBr, cm-1): 3421, 3309, 3083, 2959,
2931, 1445, 750, 698. 1H-NMR (CDCl3, 300 MHz,
δ, ppm): 1.17 (d, J = 6.2 Hz, 3H, CH-CH3), 1.91 (d,
J = 1.3 Hz, 3H, C-CH3), 2.41-2.48 (m, 3H, OH, NH,
NH-CHH), 2.75 (dd, J = 3.1 Hz, J = 9.0 Hz, 1H,
NH-CHH), 3.29-3.40 (m, 2H, CH2-NH-CH2), 3.80-
3.85 (m, 1H, CH2-CH(OH)), 6.44 (s, 1H, Ar-CH=),
7.18-7.36 (m, 5H, Ar-H). Rf = 0.37a); 0.23b); 0.26c);
miLogP = 2.377; ACD/LogP = 1.70 ± 0.33.
Analysis: calcd. for C13H19NO: C, 76.06; H, 9.33; N,
6.82%; found: C, 75.88; H, 9.55; N, 6.77%.
3-{[(2E)-2-methyl-3-phenylprop-2-en-1-yl]ami-
no}propan-1-ol hydrochloride [III]
White solid (yield 63%), m.p. 110-112OC.
M.w. = 241.76. IR (KBr, cm-1): 3423, 2947, 2797,
1446, 1061, 701. 1H-NMR (DMSO-d6, 300 MHz, δ,
ppm): 1.78-1.86 (m, 2H, CH2-CH2-CH2), 1.93 (s,
3H, C-CH3), 2.95 (bs, 2H, NH-CH2), 3.48 (t, J = 5.9
Hz, 2H, CH2-OH), 3.65 (bs, 2H, CH2-NH), 4.78 (bs,
1H, OH), 6.68 (s, 1H, Ar-CH=), 7.20-7.42 (m, 5H,
Ar-H), 9.0 (bs, 2H, NHH+). Rf = 0.57a); 0.14b); 0.18c);
miLogP = 2.284; ACD/LogP = 1.41 ± 0.29.
Analysis: calcd. for C13H20NOCl: C, 64.59; H, 8.34;
N, 5.79%; found: C, 64.27; H, 8.06; N, 5.68%.
R,S-2-{[(2E)-2-methyl-3-phenylprop-2-en-1-
yl]amino}butan-1-ol [IV]
White solid (yield 71%), m.p. 48-50OC. M.w. =
219.33. IR (KBr, cm-1): 3324, 3163, 2965, 2931,
1454, 1050, 761, 702. 1H-NMR (CDCl3, 300 MHz,
δ, ppm): 0.95 (t, J = 7.6 Hz, 3H, CH2-CH3), 1.39-
1.66 (m, 2H, CH-CH2-CH3), 1.93 (d, J = 1.3 Hz, 3H,
C-CH3), 2.21 (bs, 2H, OH, NH), 2.60-2.69 (m, 1H,
NH-CH), 3.29 (dd, J = 13.7 Hz, J = 1.0, 1H, CHH-
NH), 3.37 (dd, J = 10.8 Hz, J = 4.2 Hz, 1H, CHH-
OH), 3.42 (dd J = 13.5 Hz, J = 1.2 Hz, 1H, CHH-
NH) 3.67 (dd, J = 10.5 Hz, J = 4.0 Hz, 1H, CHH-
OH), 6.46 (s, 1H, Ar-CH=), 7.18-7.37 (m, 5H, Ar-
H). Rf = 0.41a); 0.30b); 0.39c); miLogP = 3.23;
ACD/LogP = 2.23 ± 0.33. Analysis: calcd. for
C14H21NO: C, 76.67; H, 9.65; N, 6.39%; found: C,
76.55; H, 9.81; N, 6.39%.
2-Methyl-2-{[(2E)-2-methyl-3-phenylprop-2-en-
1-yl]amino}propan-1-ol [V]
White solid (yield 75%), m.p. 47-49OC. M.w. =
219.33. IR (KBr, cm-1): 3293, 3161, 2960, 2869,
1489, 1477, 1446, 1069, 694. 1H-NMR (CDCl3, 300
MHz, δ, ppm): 1.13 (s, 6H, C(CH3)2), 1.91 (s, 3H, C-
CH3), 3.21 (s, 2H, CH2-NH), 3.33 (s, 2H, CH2-OH),
6.47 (s, 1H, Ar-CH=), 7.20-7.35 (m, 5H, Ar-H). Rf
= 0.23a); 0.20b); 0.24c); miLogP = 3.174; ACD/LogP
= 2.05 ± 0.34. Analysis: calcd. for C14H21NO: C,
76.67; H, 9.65; N, 6.39%; found: C, 76.41; H, 9.35;
N, 6.28%.
4-{[(2E)-2-methyl-3-phenylprop-2-en-1-yl]ami-
no}butan-1-ol hydrochloride [VI]
White solid (yield 69%), m.p. 126-128OC.
M.w. = 255.79. IR (KBr, cm-1): 3407, 2940, 2797,
1436, 1036, 701. 1H-NMR (DMSO-d6, 300 MHz, δ,
ppm): 1.42-1.50 (m, 2H, NH-CH2-CH2-CH2-CH2-
OH), 1.67-1.77 (m, 2H, NH-CH2-CH2-CH2-CH2-
OH), 1.98 (s, 3H, C-CH3), 2.88 (t, J = 7.8 Hz, 2H,
NH-CH2-CH2-CH2-CH2-OH), 3.41 (t, J = 6.2 Hz,
2H, NH-CH2-CH2-CH2-CH2-OH), 3.62 (s, 2H, CH2-
NH), 4.60 (bs, 1H, OH), 6.66 (s, 1H, Ar-CH=), 7.24-
7.40 (m, 5H, Ar-H), 9.07 (bs, 2H, NHH+). Rf =
0.28a); 0.15b); 0.20c); miLogP = 2.555; ACD/LogP =
1.71 ± 0.28. Analysis: calcd. for C14H22NOCl: C,
65.74; H, 8.67; N, 5.48%; found: C, 65.42; H, 8.60;
N, 5.43%.
5-{[(2E)-2-methyl-3-phenylprop-2-en-1-yl]ami-
no}pentan-1-ol hydrochloride [VII]
White solid (yield 65%), m.p. 129-131OC.
M.w. = 269.81. IR (KBr, cm-1): 3420, 2937, 2796,
1447, 1435, 1058, 1027, 701. 1H-NMR (DMSO-d6,
300 MHz, δ, ppm): 1.28-1.47 (m, 4H, -CH2-CH2-),
1.62-1.72 (m, 2H, CH2-CH2-OH), 1.94 (s, 3H, C-
CH3), 2.86 (t, J = 7.6 Hz, 2H, NH-CH2), 3.35-3.41
(m, 2H, CH2-OH), 3.63 (s, 2H, CH2-NH), 4.42 (t, J
= 5.1 Hz, 1H, OH), 6.66 (s, 1H, Ar-CH=), 7.25-
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7.41 (m, 5H, Ar-H), 8.99 (bs, 2H, NHH+). Rf =
0.39a); 0.12b); 0.19c); miLogP = 3.06; ACD/LogP =
1.94 ± 0.28. Analysis: calcd. for C15H24NOCl: C,
66.78; H, 8.97; N, 5.19%; found: C, 66.51; H, 8.96;
N, 5.17%.
R,S-2-{[(2E)-2-methyl-3-phenylprop-2-en-1-
yl]amino}-1-phenylethanol [VIII]
White solid (yield 78%), m.p. 78-80OC. M.w.
= 267.36. IR (KBr, cm-1): 3297, 3049, 3029, 2992,
1557, 1156, 618. 1H-NMR (CDCl3, 300 MHz, δ,
ppm): 1.91 (s, 3H, C-CH3), 2.76 (dd, J = 8.7 Hz, J
= 12.2 Hz, 1H, NH-CHH), 2.96 (dd, J = 3.6 Hz, J =
12.3 Hz, 1H, NH-CHH), 3.38 (s, 2H, CH2-NH),
4.75 (dd, J = 3.6 Hz, J = 8.9 Hz, Ar-CH-OH), 6.43
(s, 1H, Ar-CH=), 7.18-7.41 (m, 10H, Ar-H). Rf =
0.64a); 0.48b); 0.56c); miLogP = 3.459; ACD/LogP =
3.05 ± 0.39. Analysis: calcd. for C18H21NO: C,
80.86; H, 7.92; N, 5.24%; found: C, 81.20; H, 7.94;
N, 5.24%.
R,S-2-{[(2E)-2-methyl-3-phenylprop-2-en-1-
yl]amino}-1-phenylethanol hydrochloride [VIIIa]
White solid (yield 65%), m.p. 199-201OC.
M.w. = 303.83.
D,L-trans-2-{[(2E)-2-methyl-3-phenylprop-2-en-
1-yl]amino}cyclohexanol [IX]
White solid (yield 80%), m.p. 65-67OC. M.w. =
245.37. IR (KBr, cm-1): 3309, 3160, 2942, 2855,
1448, 1331, 1107, 1062, 895, 746. 1H-NMR (CDCl3,
300 MHz, δ, ppm): 0.98-2.35 (m, 9H, cyclohex.),
1.94 (s, 3H, C-CH3), 3.20-3.30 (m, 1H, CH-OH),
3.26 (d, J = 13.0 Hz, 1H, CHH-NH), 3.52 (d, J =
13.0 Hz, 1H, CHH-NH), 6.46 (s, 1H, Ar-CH=),
7.18-7.36 (m, 5H, Ar-H). Rf = 0.42a); 0.37b); 0.44c);
miLogP = 3.751; ACD/LogP = 2.35 ± 0.30.
Analysis: calcd. for C16H23NO: C, 78.32; H, 9.45; N,
5.71%; found: C, 77.92; H, 9.63; N, 5.68%.
trans-4-{[(2E)-2-methyl-3-phenylprop-2-en-1-
yl]amino}cyclohexanol [X]
White solid (yield 82%), m.p. 104-106OC.
M.w. = 245.37. IR (KBr, cm-1): 3259, 3246, 3098,
2930, 2860, 1374, 1106, 1070, 745, 701. 1H-NMR
(CDCl3, 300 MHz, δ, ppm): 1.14-1.36 (m, 4H,
cyclohex.), 1.45 (bs, 2H, NH, OH), 1.89 (s, 3H, C-
CH3), 1.93-2.01 (m, 4H, cyclohex.), 2.45-2.54 (m,
1H, NH-CH), 3.41 (s, 2H, CH2-NH), 3.57-3.68 (m,
1H, CH-OH), 6.43 (s, 1H, Ar-CH=), 7.17-7.36 (m,
5H, Ar-H). Rf = 0.40a); 0.16b); 0.19c); miLogP =
3.282; ACD/LogP = 2.17 ± 0.29. Analysis: calcd.
for C16H23NO: C, 78.32; H, 9.45; N, 5.71%; found:
C, 78.21; H, 9.66; N, 5.69%.
Pharmacology
Anticonvulsant activity assays
Pharmacological tests concerning anticonvul-
sant activity were performed at Epilepsy Branch,
National Institute of Neurological Disorders and
Stroke, National Institutes of Health (NIH,
Bethesda, USA) within Anticonvulsant Screening
Program (ASP). Pharmacological evaluation was
accepted by Institutional Animal Care and Use
Committee. All procedures were previously pub-
lished (16-18) as well as they are available for pub-
lic at NIH website (19). In the tests, albino mice
Carworth Farms No.1 or rats Sprague-Dawley were
used. The tested compounds were dissolved or sus-
pended in 0.5% methylcellulose. Brief descriptions
of the experiments are presented below.
MES test
Seizures were induced by delivering for 0.2 s
alternating current at 60 Hz and 50 mA (mice) or
150 mA (rats) via corneal electrodes. Protection was
defined as the abolition of the hindlimb tonic exten-
sion of the seizures. 
scPTZ test
Seizures were elicited by subcutaneous injec-
tion of pentetrazol dissolved in 0.9% NaCl at the
dose of 85 mg/kg (mice) or 70 mg/kg (rats).
Protection was scored if there was not observed
episode of clonic spasm of at least 5 s.
Neurotoxicity (TOX)
In mice, the neurological deficit was measured
by rotarod test in which a one inch diameter knurled
plastic rod rotating at 6 rpm was used. Each mouse
was placed on the rod. If it was not able to maintain
on the rod for at least 1 min in each of three trials
then neurotoxicity was scored. In rats, neurological
deficit was measured in behavioral tests and scored
when observed ataxia, loss of placing response and
muscle tone.
6-Hz test
Seizures were induced in mice by delivering
0.2 ms pulses of electric current at 6 Hz and 32 mA
for 3 s via corneal electrodes. The mouse was
released into an observation cage immediately after
stimulation. In untreated animals the duration of the
seizure activity ranges between 60 and 120 s and
afterwards they resume their exploratory behavior.
When the compounds were tested, the experiment
endpoint was protection against the seizures. The
protection was scored if the mouse resumed its nor-
mal activity within 10 s from the stimulation.
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Behavioral studies
Pharmacological tests concerning behavioral
studies were performed at Department of
Pharmacodynamics, Faculty of Pharmacy, Jagiello-
nian University Medical College. In each experi-
ment adult male CD-1 mice (18-21 g) were used.
Mice were kept in plastic cages at room temperature
(22 ± 2OC), on 12/12 h light/dark cycle. The animals
had free access to chow and water. All experiments
were carried out between 9 a.m. and 2 p.m. Each
experimental group consisted of 10 randomly select-
ed animals. Mice were used only once in each test
and killed by cervical dislocation immediately after
the experiment. Behavioral studies were fully
accepted by the First Local Ethics Committee on
Animal Testing at the Jagiellonian University in
Krakow and carried out in accordance with the
Guide to the Care and Use of the Experimental
Animals.
Forced swim test in mice
The experiment was carried out according to
the method of Porsolt et al. (20). The CD-1 mice
were individually placed in a glass cylinder (height:
25 cm; diameter: 10 cm) containing 10 cm of water
(temperature: 23ñ25OC), and were left there for 6
min. A mouse was regarded as immobile when it
remained floating on the water, making only small
movements to keep its head above it. The total dura-
tion of immobility was recorded during the last 4
min of a 6-min test session.
Four-plate test in mice
The four-plate apparatus (BIOSEB, Vitrolles)
consisted of a plastic cage floored by four identical
rectangular metal plates separated from one another
by a gap, and at the top covered by a transparent
Perspex lid that prevents escape behavior. The
plates were connected to a device that can generate
electric shocks. After a 15 s habituation period,
every time the CD-1 mouse moved from one plate to
another it was punished with an electric foot shock
(0.8 mA, 0.5 s), which was followed by a 3 s shock
interval (21). The number of punished crossings
received by mice was recorded during 1 min session.
Spontaneous locomotor activity in mice
The locomotor activity in mice was measured
with photoresistor actometers (Ugo Basile) connect-
ed to a counter for the recording of light-beam inter-
ruptions. The CD-1 mice were individually placed
in plastic cages for 30 min habituation period, and
then the number of light-beam crossings was count-
ed for 1 min or from 2nd to 6th min (time equal to
the observation period in the four-plate test or the
forced swim test, respectively). 
Biotransformation studies
In vitro mouse liver microsomal biotransforma-
tion
The incubation systems were composed of
VIIIa (20 µM in 100 mM potassium phosphate
buffer, pH 7.4), microsomes (0.8 mg/mL, mouse
liver microsomes), NADPH-regenerating system
(NADP, glucose-6-phosphate, glucose-6-phosphate
dehydrogenase in 100 mM potassium phosphate
buffer, pH 7.4), and potassium phosphate buffer
(100 mM, pH 7.4). Firstly, the mixture reactions
composed of microsomes, the tested compound and
a buffer were preincubated at 37OC for 15 min
before the addition of the NADPH-regenerating sys-
tem. The resulting mixture was incubated for 15 or
30 min at 37OC in a thermoblock and shaken during
the incubation. Then, an internal standard (levallor-
phan, 20 µM) was added to the incubation system.
The incubation was terminated at different time
points with perchloric acid (69-72%, by volume).
Thereafter, the samples were centrifuged and the
supernatant was analyzed using UPLC/MS in order
to determine the specific metabolic profile of VIIIa.
The tests without NADPH-regenerating system
were conducted in parallel. All samples were pre-
pared in duplicate (22, 23). Liver microsomal frac-
tions, NADPH regenerating system components and
levallorphan were obtained from Sigma Aldrich
(PoznaÒ, Poland). 
The UPLC-MS/MS system was composed of
Waters ACQUITYÆ UPLCÆ (Waters Corporation,
Milford, MA, USA) coupled to a Waters TQD mass
spectrometer (electrospray ionization mode ESI-tan-
dem quadrupole). Chromatographic separations
were done with an Acquity UPLC BEH (bridged
ethyl hybrid) C18 column; 2.1 ◊ 100 mm, and 1.7 µm
particle size. The column was maintained at 40OC,
and eluted under gradient conditions using from
95% to 0% of eluent A over 10 min, at a flow rate of
0.3 mL/min. Eluent A: water/formic acid (0.1%,
v/v). 10 µL of each sample were injected. Chromato-
grams were recorded using a Waters λ PDA detec-
tor. Spectra were analyzed in 200-700 nm range
with 1.2 nm resolution and a sampling rate 20
points/s.
MS detection settings of the Waters TQD mass
spectrometer were as follows: source temperature
150OC, desolvation temperature 350OC, desolvation
gas flow rate 600 L/h, cone gas flow 100 L/h, capil-
lary potential 3.00 kV, cone potential 20 V. Nitrogen
was used as both nebulizing and drying gas. The data
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were obtained in a scan mode ranking from 50 to
1000 m/z in 0.5 s time intervals; 8 scans were
summed up to get the final spectrum. Collision acti-
vated dissociation (CAD) analyses were carried out
with energy of 20 eV, and all the fragmentations were
observed in the source. The ion spectra were obtained
by scanning from 50 to 500 m/z range. The data
acquisition software was MassLynx V 4.1 (Waters). 
In silico prediction of metabolism
MetaSite, Molecular Discovery Ltd., v. 5.0.3 is a
computational model that enables the prediction of
CYP450-dependent metabolism in phase I biotrans-
formations. The software indicates the atoms in a mol-
ecule structure that are mostly vulnerable to metabol-
ic changes with cytochromes. Validation procedures
have proved that in 85% of the analyzed structures the
indicated metabolic sites agreed in top three rankings
with experimental data (24, 25). Additionally,
MetaSite predicts the chemical structures of the most
probable metabolites and enables the identification of
cytochrome isoform(s) responsible for the metabolism
of substrates (26). The probability of a specific atom i
to be a site of metabolism catalyzed by the heme moi-
ety of CYP450 depends on several factors, such as the
accessibility of atom i towards the heme (indicated as
Ei); the chemical reactivity of atom i in the specific
reaction mechanism (described as Ri) and the relative
probability of a reaction mechanism under considera-
tion occurring (called Mi). Thus, the probability func-
tion (PSMi) for a specific atom i can be defined by the
following equation (24, 25): 
PSMi = Ei ◊ Ri ◊ Mi 
Serotonin 5-HT receptors binding assays
Cell culture and preparation of cell membranes
HEK293 cells with stable expression of human
serotonin 5-HT1AR, 5-HT6 or 5-HT7bR (prepared
with the use of Lipofectamine 2000) were main-
tained at 37OC in a humidified atmosphere with 5%
CO2 and were grown in Dulbeccoís modified
Eagleís medium containing 10% dialyzed fetal
bovine serum and 500 µg/mL G418 sulfate. For
membranes preparations, cells were subcultured in
10 cm diameter dishes, grown to 90% confluence,
washed twice with prewarmed to 37OC phosphate
buffered saline (PBS) and were pelleted by centrifu-
gation (200 ◊ g) in PBS containing 0.1 mM EDTA
and 1 mM dithiothreitol. Prior to membrane prepa-
rations pellets were stored at ñ80OC.
Radioligand binding assays
Cell pellets were thawed and homogenized in
20 volumes of assay buffer using an Ultra Turrax
tissue homogenizer and centrifuged twice at 35 000
◊ g for 20 min at 4OC, with incubation for 15 min at
37OC in between. The composition of the assay
buffers was as follows: for 5-HT1AR: 50 mM
TrisñHCl, 0.1 mM EDTA, 4 mM MgCl2, 10 µM par-
gyline and 0.1% ascorbate; for 5-HT6R: 50 mM
TrisñHCl, 0.5 mM EDTA and 4 mM MgCl2, for 5-
HT7bR: 50 mM TrisñHCl, 4 mM MgCl2, 10 µM par-
gyline and 0.1% ascorbate.
All assays were incubated in a total volume of
200 µL in 96-well microtitre plates for 1 h at 37OC,
except for 5-HT1AR which were incubated at room
temperature for 1 h. The process of equilibration is
terminated by rapid filtration through Unifilter
plates with a 96-well cell harvester and radioactivi-
ty retained on the filters was quantified on a
Microbeta plate reader. For displacement studies the
assay samples contained as radioligands: 1.5 nM
[3H]-8-OH-DPAT (187 Ci/mmol) for 5-HT1AR; 2
nM [3H]-LSD (85.2 Ci/mmol for 5-HT6R or 0.6 nM
[3H]-5-CT (39.2 Ci/mmol) for 5-HT7R. Non-specif-
ic binding was defined with 10 µM of 5-HT in 5-
HT1AR and 5-HT7R binding experiments, whereas
10 µM methiothepine was used in 5-HT6R assays. 
Each compound was tested in triplicate at 7ñ8
concentrations (10-11ñ10-4 M). The inhibition con-
stants (Ki) were calculated from the Cheng-Prusoff
equation (27). Results were expressed as means of at
least two separate experiments. Membrane prepara-
tion and general assay procedures for cloned recep-
tors were adjusted to 96-microwell format based on
protocols described by us previously (28, 29).
RESULTS
Chemistry
Synthetic route and structures of the tested
compounds are shown in Table 1. Compounds were
obtained in simple two-steps procedure consisting of
condensation of (E)-α-methylcinnamaldehyde and
appropriate aminoalkanol followed by reduction of
obtained Schiff bases by means of sodium borohy-
dride. 
The search in SciFinder database indicated that
some of the structures are already known, anyway,
CAS numbers are not available for single E enan-
tiomers but for compounds with undefined
stereoisomeric function. For I (CAS: 1603924-12-
4), II (CAS: 1563930-71-1), and VII (CAS:
1562359-97-0 for base) only calculated physico-
chemical data are available but there are neither ref-
erences nor biological activity results available. For
III (CAS: 722551-27-1 for base, CAS: 1375800-64-
8 for enantiomer E as base) method of synthesis was
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published (30) but there is no information about bio-
logical activity.
All presented compounds did not show any
violations from Lipinskiís ìrule of fiveî (31) mak-
ing them potentially promising drug-like agents.
The partition coefficient (log P) ranged from 1.41 ±
0.29 to 3.05 ± 0.39 when calculated by means of
ACDLabs and from 2.284 to 3.751 when calculated
by means of molinspiration on-line tool (for details
see Experimental section).
Anticonvulsant activity
Anticonvulsant activity and neurotoxicity were
evaluated within Anticonvulsant Screening Program
Table 3. Anticonvulsant activity in 6-Hz test of compounds I and VI (mice, i.p., 32 mA).
Compound Test
Dose Time [h]
[mg/kg b.w.] 0.25 0.5 1.0 2.0 4.0
I 
6-Hza) 100 4/4 3/3 1/3 0/3 0/4
TOXb) 100 4/4 2/3 1/4(1) 1/4(1) 0/4  
VI
6-Hza) 50 0/4 0/4 0/4 0/4 0/4
TOXb) 50 0/4 0/4 0/4 0/4 0/4  
a) Number of animals protected/number of animals tested in the 6-Hz test; b) Number of animals displaying neurotoxicity/number of animals
used in the rotarod test, number in parentheses indicates deaths.
Table 2. Anticonvulsant activity of the tested compounds in mice after i.p. administration.
Dose MES
a) scPTZa) TOXb)
Compound
[mg/kg b.w.] 0.5 h 4.0 h 0.5 h 4.0 h 0.5 h 4.0 h  
3 0/4 - - - 0/4 - 
10 0/4 - - - 0/4 - 
I 30 1/1 0/1 0/1 0/1 0/4 0/2
100 1/3 0/3 0/1 0/1 0/8 0/4
300 - - - - 4/4(4) -
30 0/1 0/1 0/1 0/1 0/4 0/2
II 100 3/3 0/3 0/1 0/1 4/8(1) 0/4
300 - - - - 4/4(4) - 
30 0/1 0/1 0/1 0/1 0/4 0/2
III 100 0/3 0/3 0/1 0/1 0/8 0/4
300 - - 0/1 - 3/4(3) -  
30 0/1 0/1 0/1 0/1 1/4 0/2
IV 100 1/3 1/3 - 0/1 1/8(1) 0/4
300 1/1 - - - 3/4(3) -  
30 0/1 0/1 0/1 0/1 0/4 0/2
V 100 3/3 0/3 0/1 0/1 0/8 0/4
300 1/1 - 0/1 0/1 4/4(1) 0/1  
30 01 0/1 0/1 0/1 0/4 0/2
VII 100 2/3 0/3 0/1 0/1 3/8 0/4
300 - - - - 4/4(4) -
30 0/1 0/1 0/1 0/1 0/4 0/2
VIII 100 2/2 0/1 0/1 - 8/8(4) 1/2(1)
300 - - - - 4/4(4) -  
30 0/1 0/1 0/1 0/1 0/4 0/2
IX 100 2/2 0/3 - - 6/8(3) 0/3
300 - - - - 4/4(4) -  
X 30 0/1 0/1 0/1 0/1 0/4 0/2
100 3/3 0/3 0/1 0/1 4/8 0/4
300 - - - - 4/4(4) -   
a) Number of animals protected/number of animals used in the MES or scPTZ test; b) Number of animals displaying neurotoxicity/number
of animals used in the rotarod test, number in parentheses indicates number of observed deaths; - the compound was not tested in this par-
ticular case. 
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(ASP) at National Institute of Neurological Disorders
and Stroke, National Institutes of Health, Bethesda,
USA (19). Nine compounds [I-V, VII-X] were sub-
jected to standard procedures including three tests:
maximal electroshock (MES) and subcutaneous pen-
tetrazole (scPTZ) tests for anticonvulsant activity as
well as neurotoxicity evaluation by means of rotarod
test. The evaluations were performed in mice after 0.5
and 4 h of intraperitoneal (i.p.) administration of the
compounds. Compound VI was qualified to modified
protocol involving prior evaluation in 6-Hz test for
anti-seizure activity and rotarod for neurotoxicity
while MES and scPTZ tests were omitted for it.
Compound I was tested in 6-Hz after successful
screen in MES. In addition, compounds I, IV and VII
were evaluated in rats after oral administration. 
Most of the compounds proved their activity in
mice after i.p. administration in MES, especially at
100 mg/kg, compound I additionally at 30 mg/kg.
The compounds were not active in scPTZ model.
Among the series relatively high neurotoxicity was
observed, both at 300 mg/kg and 100 mg/kg (Table
2). Compound I was chosen for evaluation in 6-Hz
test in mice and proved beneficial protective activi-
ty at the dose of 100 mg/kg. The activity was accom-
panied by neurotoxicity at the same time points and
dose. Compound VI did not show neither activity
nor neurotoxicity in this model (Table 3).
Compounds I, IV and VII were tested in rats after
oral administration but none of them proved any
beneficial properties (data not shown).
Antidepressant-like activity of compound VIIIa
in mice
Compound VIIIa at the doses 20 and 30 mg/kg
(but not 10 mg/kg) significantly decreased immobil-
Table 4. Antidepressant-like activity of compound VIIIa in the forced swim test in mice.
Immobility time
Compound Dose Mean ± SEM
[mg/kg b.w.] [s]
Vehicle - 166.9 ± 13.1
10 155.9 ± 14.9
VIIIa 20 94.3 ± 13.3** 
30 111.3 ± 16.1*
Vehicle - 165.2 ± 11.7
Mianserin
5 136.3 ± 10.8
10 125.9 ± 10.8*
Compound VIIIa and mianserin were dissolved in 0.9% NaCl, and administered i.p. 30 min before the test. The
control groups received 0.9% NaCl. Statistical analysis: one-way ANOVA (Newman-Keuls post hoc test) *p <
0.05, **p < 0.01 vs. respective vehicle-treated group; n = 10 mice per group.
Table 5. Anxiolytic-like activity of compound VIIIa in the four-plate test in mice.
Number of punished
Compound 
Dose
crossings[mg/kg b.w.]
Mean ± SEM
Vehicle - 3.2 ± 0.3
1.25 4.0 ± 0.4
2.5 5.0 ± 0.5*
5 5.5 ± 0.4**
VIIIa
10 5.4 ± 0.4**
20 4.9 ± 0.4*
30 7.3 ± 0.4****
Vehicle - 3.1 ± 0.4
Medazepam
1 4.3 ± 0.4
2 6.5 ± 0.7***
Compound VIIIa and medazepam were dissolved in 0.9% NaCl, and administered i.p. 30 and 60 min before
the test, respectively. The control groups received 0.9% NaCl. Statistical analysis: one-way ANOVA
(Newman-Keuls post hoc test) *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. respective vehicle-treat-
ed group; n = 10 mice per group.
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ity in mice by 43.5% and 33.3%, respectively
(F(3,36) = 5.866, p < 0.01). Mianserin, used as a ref-
erence drug, administered at the dose 10 mg/kg (but
not 5 mg/kg) statistically decreased immobility in
mice by 23.8% (F(2,27) = 3.367, p < 0.05). The
results are presented in Table 4.
Anxiolytic-like activity of compound VIIIa in
mice
Compound VIIIa at the doses 2.5, 5, 10, 20,
and 30 mg/kg (but not 1.25 mg/kg) significantly
increased the number of punished crossings in mice
by 56.3, 71.9, 68.8, 53.1 and 128.1%, respectively
(F(6,63) = 9.529, p < 0.0001). The reference anxi-
olytic drug - medazepam administered at a dose 2
mg/kg (but not 1 mg/kg) significantly increased the
number of punished crossings in mice by 109.7%
(F(2,27) = 10.63, p < 0.001). The results are pre-
sented in Table 5.
The influence of VIIIa on locomotor activity in
mice
In the 4-min session, compound VIIIa inject-
ed at the doses 20 and 30 mg/kg (i.e., doses active
in FST in mice) did not influence locomotor activ-
ity in mice (F(2,27) = 0.2109, ns). In 1-min ses-
sion compound VIIIa administered at the doses
2.5-30 mg/kg (i.e., doses active in four-plate test
in mice) did not affect locomotor activity in mice
(F(5,54) = 0.6500, ns). The results are presented in
Table 6.
In vitro and in silico prediction of metabolism of
compound VIIIa
The metabolism of compound VIIIa in mouse
liver microsomes was studied in vitro at two differ-
ent time points i.e., after 15 and 30 min. After 15
min of incubation, two major metabolites (M1 and
M2) were found. Moreover, after 30 min of incuba-
tion, additional two metabolites (M3 and M4) were
observed. The chemical structures of metabolites
were proposed on the basis of ion fragmentation and
liquid chromatography results (Table 7). MetaSite
software indicated that CYP2D6, 2C9, 2C19 and
3A4 were primarily involved in the formation of
metabolites M1 and M4, whereas CYP2C9 and 3A4
were predicted to contribute to the formation of M2
and M3 metabolites (Fig. 1). 
Table 7. Retention times, mass characteristics and elemental composition of the [M + H]+ of compound VIIIa and its four metabolites.
Compound
Retention time Metabolic % content among
[min] 
[M + H]+ 
reaction  metabolites
VIIIa 4.52 268 - - 
M1 3.09 300 Aliphatic and aromatic 71.7
hydroxylation 
M2 3.45 284 Aliphatic carbonylation 23.3
M3 2.81 316 Aliphatic carbonylation 2.9
M4 2.72 300 Aromatic hydroxylation 2.1
Table 6. The effect of compound VIIIa administered at the doses active in forced swim test and four-plate test
on locomotor activity in mice.
Locomotor activity: number of crossings during:
Compound Dose 1 min 4 min
[mg/kg b.w.]     Mean ± SEM Mean ± SEM
Vehicle - 32.1 ± 5.6 226.1 ± 16.9
2.5 31.8 ± 4.8  - 
5 2 4.7 ± 5.1  -
VIIIa 10 26.5 ± 5.0 - 
20 36.1 ± 6.4 214.2 ± 19.2
30 28.5 ± 4.5 200.2 ± 41.7
Compound VIIIa was dissolved in 0.9% NaCl and administered i.p. 30 before the test. The control groups
received 0.9% NaCl. Statistical analysis: one-way ANOVA (Newman-Keuls post hoc test); n = 10 mice per
group.
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Serotonin receptors binding results
The tested compounds did not show significant
binding affinities to serotonin receptors 5-HT1A, 5-
HT6, and 5-HT7 (Table 8). Compound VIII, which
possesses additional hydrophobic domain in
aminoalkanol moiety proved the lowest 5-HT1A
inhibition constant among the tested series but still
not sufficient for concluding about its molecular
mechanism of action.
DISCUSSION AND CONCLUSION
The anticonvulsant activity proved by means of
animal models do not depend on particular molecu-
lar mechanism of action thus animal models enable
efficient screening of relatively large number of
compounds. MES - electrically induced seizures and
scPTZ - chemically induced seizures tests have been
considered as ìgold standardsî in the discovering of
new antiepileptic drugs, they enabled the identifica-
tion of most of the currently marketed antiepileptic
drugs (4). On the other hand, despite introducing of
many new antiepileptic drugs, the percentage of fail-
ure in epilepsy pharmacotherapy remains over last
few decades at constant level of 30% of patients. As
the consequence, some models of resistant seizures
were introduced at the early stages of antiepileptics
development as a hope for identification of new com-
pounds effective in resistant epilepsy in humans. One
of such tests is 6-Hz psychomotor seizure model in
mice (32, 33). The presented compounds were qual-
ified either to standard anticonvulsant evaluation
(MES, scPTZ, rotarod - compounds I-V, VII-X) or
modified procedures (6-Hz, rotarod - compound VI).
Table 8. Results of binding to serotonin receptors of reference and selected tested compounds.
Compound Ki [nM]
5-HT1A 5-HT6 5-HT7
I 14200 10830 16060
II 19590 7232 6793
III 9415 15760 6384
IV 5016 3054 3018
V 20110 15980 20710
VII 1787 13540 17240
VIII 456 5913 5559
IX 4902 11560 4808
X 20008 19720 16910
Buspirone 12 - -
Clozapine 143 4 18
Radioligand binding assays to rats brain tissues using [3H]-8-OH-DPAT for 5-HT1A, [3H]-LSD for 5-HT6, [3H]-
5-CT for 5-HT7. Inhibition constants (Ki) were calculated according to the equation of Cheng and Prusoff (27).
Figure 1. Metabolic pathways of compound VIIIa in mouse liver microsomes
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The reported series of compounds I-X possess
some domains regarded as beneficial for anticonvul-
sant activity. Both currently available antiepileptic
drugs and compounds in preclinical development
may be characterized by possessing pharmacophor-
ic elements such as at least one hydrophobic ring
and at least two hydrogen bonding donor/acceptor
functions (7). We have previously reported anticon-
vulsant activity of trans-cinnamyl derivatives of
aminoalkanols which proved diverse protective
activity in MES test (13). Currently reported com-
pounds possess additional methyl substituent in cin-
namyl moiety. The compounds in preliminary
screening showed some protective properties in
MES test but not in scPTZ evaluation. The neuro-
toxicity was also noted but mostly at the doses high-
er than active ones. In case of 2-aminopropan-1-ol
derivative introduction of methyl substituent caused
significant increase of activity in 6-Hz test, which is
concerned as the test predictive for resistant seizures
in humans.
The derivative of 2-amino-1-phenyletanol dif-
fers from other reported substances in possessing
additional hydrophobic ring in aminoalkanol moiety
(Fig. 2). We have chosen that compound for evalua-
tion of antidepressant- and anxiolytic-like activity
and it proved promising properties.
The results of our study indicate that com-
pound VIIIa showed antidepressant-like effect in
the forced swim test in mice. Interestingly, it pro-
duced a U-shaped dose-response curve, which is a
very common effect for antidepressants and com-
pounds with antidepressant-like activity (34). It is
worth noting that the activity of compound VIIIa in
this test was weaker than that of mianserin, a refer-
ence antidepressant drug. As compound VIIIa did
not affect locomotor activity in mice at the dose
active in the forced swim test, its antidepressant-like
activity cannot be attributed to the psychostimulant
action. Furthermore, compound VIIIa showed a
dose-dependent anxiolytic-like activity in the four-
plate test in mice. Its effect was comparable in term
of active doses to medazepam - a reference anxi-
olytic drug. Given the fact that compound VIIIa
administered at the doses active in the four-plate test
did not influence locomotor activity in mice during
1-min session, it can be concluded that the observed
anxiolytic-like effect was specific. 
The current study demonstrated a low stability
of compound VIIIa as after 30 min of biotransfor-
mation there was no remaining parent compound in
the incubation mixture and four metabolites were
observed. This important metabolic data may help in
further understanding the observed pharmacological
effects of compound VIIIa. However, additional
experiments should be performed in order to assess
the activity of its metabolites.
Finally, the weak results of binding affinities to
serotonin receptors 5-HT1A, 5-HT6, and 5-HT7 of the
tested compounds are not sufficient for concluding
about their molecular mechanism of action.
Compound VIII, which proved anticonvulsant, anti-
depressant-, and anxiolytic-like activities showed
lowest 5-HT1A inhibition constant among the tested
series. That result may suggest beneficial role of
additional hydrophobic domain in aminoalkanol
moiety in interaction with molecular targets result-
ing in promising activity in central nervous system.
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